Literature DB >> 32205483

Automated Quantitation of CD8-positive T Cells Predicts Prognosis in Colonic Adenocarcinoma With Mucinous, Signet Ring Cell, or Medullary Differentiation Independent of Mismatch Repair Protein Status.

Douglas J Hartman1, Madison Frank1, Lindsey Seigh1, Haroon Choudry2, James Pingpank2, Matthew Holtzman2, David Bartlett2, Nathan Bahary3, Liron Pantanowitz1, Reetesh K Pai1.   

Abstract

Despite their association with DNA mismatch repair (MMR) protein deficiency, colonic adenocarcinomas with mucinous, signet ring cell, or medullary differentiation have not been associated with improved survival compared with conventional adenocarcinomas in most studies. Recent studies indicate that increased T-cell infiltration in the tumor microenvironment has a favorable prognostic effect in colonic adenocarcinoma. However, the prognostic effect of tumor-associated T cells has not been evaluated in histologic subtypes of colonic adenocarcinoma. We evaluated CD8-positive T-cell density in 259 patients with colonic adenocarcinoma, including 113 patients with tumors demonstrating mucinous, signet ring cell, or medullary differentiation, using a validated automated quantitative digital image analysis platform and correlated CD8-positive T-cell density with histopathologic variables, MMR status, molecular alterations, and survival. CD8-positive T-cell densities were significantly higher for MMR protein-deficient tumors (P<0.001), BRAF V600E mutant tumors (P=0.004), and tumors with medullary differentiation (P<0.001) but did not correlate with mucinous or signet ring cell histology (P>0.05 for both). In the multivariable model of factors predicting disease-free survival, increased CD8-positive T-cell density was associated with improved survival both in the entire cohort (hazard ratio=0.34, 95% confidence interval, 0.15-0.75, P=0.008) and in an analysis of patients with tumors with mucinous, signet ring cell, or medullary differentiation (hazard ratio=0.06, 95% confidence interval, 0.01-0.54, P=0.01). The prognostic effect of CD8-positive T-cell density was independent of tumor stage, MMR status, KRAS mutation, and BRAF mutation. Venous invasion was the only other variable independently associated with survival in both the entire cohort and in patients with tumors with mucinous, signet ring cell, or medullary differentiation. In summary, our results indicate that the prognostic value of MMR protein deficiency is most likely attributed to increased tumor-associated CD8-positive T cells and that automated quantitative CD8 T-cell analysis is a better biomarker of patient survival, particularly in patients with tumors demonstrating mucinous, signet ring cell, or medullary differentiation.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32205483      PMCID: PMC7364820          DOI: 10.1097/PAS.0000000000001468

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.298


  51 in total

1.  Objective criteria for crohn-like lymphoid reaction in colorectal cancer.

Authors:  Hideki Ueno; Yojiro Hashiguchi; Hideyuki Shimazaki; Eiji Shinto; Yoshiki Kajiwara; Kuniaki Nakanishi; Kei Kato; Kazuya Maekawa; Kosuke Miyai; Takahiro Nakamura; Junji Yamamoto; Kazuo Hase
Journal:  Am J Clin Pathol       Date:  2013-04       Impact factor: 2.493

2.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Authors:  Dung T Le; Jennifer N Durham; Kellie N Smith; Hao Wang; Bjarne R Bartlett; Laveet K Aulakh; Steve Lu; Holly Kemberling; Cara Wilt; Brandon S Luber; Fay Wong; Nilofer S Azad; Agnieszka A Rucki; Dan Laheru; Ross Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Tim F Greten; Austin G Duffy; Kristen K Ciombor; Aleksandra D Eyring; Bao H Lam; Andrew Joe; S Peter Kang; Matthias Holdhoff; Ludmila Danilova; Leslie Cope; Christian Meyer; Shibin Zhou; Richard M Goldberg; Deborah K Armstrong; Katherine M Bever; Amanda N Fader; Janis Taube; Franck Housseau; David Spetzler; Nianqing Xiao; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; James R Eshleman; Bert Vogelstein; Robert A Anders; Luis A Diaz
Journal:  Science       Date:  2017-06-08       Impact factor: 47.728

3.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

Review 4.  Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016.

Authors:  Alessandro Lugli; Richard Kirsch; Yoichi Ajioka; Fred Bosman; Gieri Cathomas; Heather Dawson; Hala El Zimaity; Jean-François Fléjou; Tine Plato Hansen; Arndt Hartmann; Sanjay Kakar; Cord Langner; Iris Nagtegaal; Giacomo Puppa; Robert Riddell; Ari Ristimäki; Kieran Sheahan; Thomas Smyrk; Kenichi Sugihara; Benoît Terris; Hideki Ueno; Michael Vieth; Inti Zlobec; Phil Quirke
Journal:  Mod Pathol       Date:  2017-05-26       Impact factor: 7.842

5.  Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.

Authors:  Bernhard Mlecnik; Marie Tosolini; Amos Kirilovsky; Anne Berger; Gabriela Bindea; Tchao Meatchi; Patrick Bruneval; Zlatko Trajanoski; Wolf-Herman Fridman; Franck Pagès; Jérôme Galon
Journal:  J Clin Oncol       Date:  2011-01-18       Impact factor: 44.544

Review 6.  Mucinous subtype as prognostic factor in colorectal cancer: a systematic review and meta-analysis.

Authors:  J Verhulst; L Ferdinande; P Demetter; W Ceelen
Journal:  J Clin Pathol       Date:  2012-01-18       Impact factor: 3.411

7.  Clinical impact of tumor-infiltrating lymphocytes for survival in stage II colon cancer.

Authors:  Won-Suk Lee; Sanghui Park; Woo Yong Lee; Seong Hyeon Yun; Ho-Kyung Chun
Journal:  Cancer       Date:  2010-11-15       Impact factor: 6.860

8.  Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.

Authors:  David S Williams; Dmitri Mouradov; Robert N Jorissen; Marsali R Newman; Elham Amini; David K Nickless; Julie A Teague; Catherine G Fang; Michelle Palmieri; Marie J Parsons; Anuratha Sakthianandeswaren; Shan Li; Robyn L Ward; Nicholas J Hawkins; Ian Faragher; Ian T Jones; Peter Gibbs; Oliver M Sieber
Journal:  Gut       Date:  2018-01-30       Impact factor: 23.059

9.  Prognostic Utility of Immunoprofiling in Colon Cancer: Results from a Prospective, Multicenter Nodal Ultrastaging Trial.

Authors:  Devin C Flaherty; Simon Lavotshkin; John R Jalas; Hitoe Torisu-Itakura; Daniel D Kirchoff; Myung S Sim; Delphine J Lee; Anton J Bilchik
Journal:  J Am Coll Surg       Date:  2016-03-18       Impact factor: 6.113

10.  Microsatellite instability is associated with reduced disease specific survival in stage III colon cancer.

Authors:  H M Mohan; E Ryan; I Balasubramanian; R Kennelly; R Geraghty; F Sclafani; D Fennelly; R McDermott; E J Ryan; D O'Donoghue; J M P Hyland; S T Martin; P R O'Connell; D Gibbons; Des Winter; K Sheahan
Journal:  Eur J Surg Oncol       Date:  2016-06-22       Impact factor: 4.424

View more
  3 in total

1.  Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis.

Authors:  Chaoyuan Kuang; Yongseok Park; Ryan C Augustin; Yan Lin; Douglas J Hartman; Lindsey Seigh; Reetesh K Pai; Weijing Sun; Nathan Bahary; James Ohr; John C Rhee; Stanley M Marks; H Scott Beasley; Yongli Shuai; James G Herman; Hassane M Zarour; Edward Chu; James J Lee; Anuradha Krishnamurthy
Journal:  Clin Epigenetics       Date:  2022-01-06       Impact factor: 6.551

2.  CD8-positive T cells and CD204-positive M2-like macrophages predict postoperative prognosis of very high-risk prostate cancer.

Authors:  Yoshinori Yanai; Takeo Kosaka; Shuji Mikami; Hiroshi Hongo; Yota Yasumizu; Toshikazu Takeda; Kazuhiro Matsumoto; Jun Miyauchi; Shigehisa Kitano; Mototsugu Oya
Journal:  Sci Rep       Date:  2021-11-18       Impact factor: 4.379

Review 3.  The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis.

Authors:  Maria Wozniakova; Jozef Skarda; Milan Raska
Journal:  Pathol Oncol Res       Date:  2022-07-21       Impact factor: 2.874

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.